Recent data indicate that the human pathogen group B Streptococcus (GBS) produces pilus-like structures encoded in genomic islands with similar organization to pathogenicity islands. On the basis of the amino acid sequence of their protein components, 3 different types of pili have been identified in GBS, at least 1 of which is present in all isolates. We recently demonstrated that recombinant pilus proteins protect mice from lethal challenge with GBS and are thus potential vaccine candidates. Here, we show that GBS pilin island 1, transferred into the nonpathogenic microorganism Lactococcus lactis, leads to pilus assembly. We also show that systemically or mucosally delivered Lactococcus expressing pilin island 1 protects mice from challenge with GBS isolates carrying pilus 1. Furthermore, lactococci engineered to express hybrid pili containing GBS pilus 1 and pilus 2 components confer protection against strains expressing either of the 2 pilus types. These data pave the way to the design of pilus-based, multivalent live vaccines against streptococcal pathogens.
Bacterial pili or fimbriae are protruding filaments composed of proteins that perform various functions, among which that of assisting host colonization and infection by providing adhesive properties is particularly relevant [1] . We recently discovered the presence of pili in Streptococcus agalactiae (group B Streptococcus; GBS) [2] , which is the foremost cause of life-threatening bacterial infections in newborns [3] . Similar to other gram-positive pathogens [4, 5] , GBS pili appear as long-extending appendages that protrude outside of the bacterial cell.
Multistrain genome analysis allowed the identification in GBS of 3 types of pili, which are composed of partially homologous proteins [6, 7] . They are encoded in 3 genomic islands, each containing 3 genes coding for the LPXTG proteins that compose the pilus and 2 genes coding for sortases directly involved in pilus formation. At least 1 of the 3 pilus types is present in all 8 sequenced GBS genomes [6] , and a recent epidemiological analysis of a panel of 37 clinical isolates indicated that 78% of the strains expressed pilus 1 and/or pilus 2 proteins at high levels [8] . Remarkably, in the same study, we demonstrated that vaccines based on combinations of recombinant pilus components from island 1 and island 2 protected mice against lethal challenge with a wide variety of GBS strains.
Genomic islands similar to those responsible for pilus assembly in GBS have also been found in Streptococcus pyogenes and Streptococcus pneumoniae, and this observation led to the discovery of analogous structures in these 2 other major human pathogens [9, 10] . Moreover, evidence that pilus components confer protection against S. pyogenes was obtained using a mouse model of intranasal challenge [9] .
In view of their wide distribution and capacity to elicit protective activities, pilin elements can become key tools for future vaccine formulations against strep- tococcal diseases. However, considering the complexity of fimbrial organization and the variability in pilus composition among strains [7, 9] , the development of pili-based vaccines may be hampered by the number of components required to achieve broad coverage.
In the present study, we show that the food-grade microorganism Lactococcus lactis can be engineered to produce GBS pili and that recombinant lactococci expressing pilus components confer protection against GBS lethal challenge on systemic and mucosal immunization. Furthermore, we demonstrate that hybrid pili comprising island 1 and island 2 elements can be assembled in L. lactis and that bacteria carrying such hybrid structures confer protection against island 1-and island 2-specific GBS strains. Taken together, these data indicate that fimbriae from different streptococcal isolates can be functionally expressed in nonpathogenic bacteria to obtain multivalent live vaccines against overwhelming streptococcal diseases.
MATERIALS AND METHODS
Bacterial strains. Escherichia coli BL21(DE3) was grown in Luria broth (Difco). L. lactis subspecies cremoris MG1363 [11] was grown in M17 (Difco) supplemented with 0.5% glucose (GM17). Selective media contained 20 mg of chloramphenicol per mL. S. agalactiae serotype III strains 515 [11] and COH1 [12] were grown in Todd-Hewitt broth (Difco).
Plasmid construction. General procedures for DNA manipulation were performed using standard methodologies. Plasmid constructs were derived from the shuttle vector pAM401 [13] , first established in E. coli and then transferred into L. lactis electrocompetent cells [14] . Isolation of plasmid DNA from Lactococcus was performed as described elsewhere [15] . DNA amplification primers are reported in table 1.
Cloning of GBS open reading frames (ORFs) was performed in 3 steps. First, we obtained an expression vector suitable for Lactococcus (pAM-P80) by introducing into pAM401 two intergenic regions comprising the predicted promoter element and the r-independent transcription terminator of GBS80 ORF. The 2 DNA fragments were amplified as a single splicing-byoverlap-extension PCR product by use of primers 1-4 and COH1 DNA as template. Unique restriction sites NotI and BglII were introduced between the 2 elements to allow further cloning of GBS ORFs.
In a second step, genes GBS80, GBS104, and the whole DNA region from GBS80 to GBS104 were amplified from COH1 genome by use of primers 5-6, 7-8, and 5-8, respectively, and were inserted into pAM-P80 to obtain plasmids pAM-GBS80, pAM-GBS104, and pAM-Is1.
Plasmid pAM-Is1-2 was obtained in a third step by amplifying GBS67 ORF (island 2) from 515 DNA by using primers 9-10 and by introducing the PCR product into pAM-Is1 in place of GBS104, between XbaI-BglII unique sites. To obtain pAM-GBS67 expressing the protein alone under its own promoter, we introduced into pAM401, between SalI and EagI sites, a PCR product derived from GBS 515 using primers 11 and 12.
Cloning, expression, and purification of recombinant proteins in E. coli and preparation of immune serum samples and monoclonal antibodies are described elsewhere [8] . GenBank accession numbers of expressed GBS proteins are ZP_00784492, ZP_00784487, and ZP_00784518 for GBS80, GBS52, and GBS104, respectively, from COH1 and ZP_00789553 for GBS67 from 515.
Immunoblotting, flow cytometry, and electron microscopy. For immunoblot analysis, L. lactis and S. agalactiae pellets from 50-mL late-exponential-phase cultures were incubated at 37ЊC for 3 h in 1 mL lysis buffer (50 mM Tris-HCl, pH 6.8; protease inhibitors [Roche]; 4 mg lysozyme [Roche] ; and 400 units of mutanolysin [Sigma] ). After 3 cycles of freeze-thaw and centrifugation, the supernatants were concentrated (Centricon filter units; Millipore), and the protein concentration was measured with the Bio-Rad protein assay (Bio-Rad). Cell extracts were separated on 3%-8% SDS-PAGE and were electroblotted as described elsewhere [2] . Fluorescence-activated cell-sorting analysis using polyclonal and monoclonal mouse serum samples was performed using bacteria grown to late exponential phase, as described elsewhere [8] . Lactococcus immunogold labeling and transmission electron microscopy was performed as reported elsewhere for GBS [2] .
Mouse model, ELISA, and opsonophagocytosis. Groups of 4-8 five-week-old female CD1 mice (Charles River) received 3 doses of live lactococci in PBS or 20 mg of purified antigen per dose or PBS. Purified proteins were combined with or without complete Freund adjuvant at priming and incomplete Freund adjuvant at the following boosts. Mice were immunized subcutaneously, intraperitoneally, or intranasally at days 0, 14, and 28. Mice that were vaccinated intranasally received 3 consecutive daily doses at 2-week intervals. At least 2 immunization experiments were performed for each combination of antigen and immunization route.
At day 33, immunized mice were mated, and the offspring were challenged intraperitoneally 24 h after birth with a dose of GBS calculated to kill 90% of pups. Survival was monitored for 2 days after challenge, and statistical analysis was performed using Fisher's exact test. All animal studies were performed according to the guidelines of the Italian Istituto Superiore di Sanità.
Serum samples, nasal wash samples (200 mL), and vaginal wash samples (500 mL) (washes made with PBS, 0.1% bovine serum albumin, and protease inhibitors) were collected on days 0 and 42. Antigen-specific systemic or mucosal antibody responses were detected by ELISA, as described elsewhere [16] , by use of 0.1 mg of purified recombinant antigens per well. IgG antibody titers were calculated by comparing the response curve of test serum samples with that of reference serum samples by using a reference line calculation program. The reference serum samples were a pool of serum samples obtained from mice immunized with the purified recombinant antigen, to which an arbitrary titer of 150,000 EU/mL was assigned. IgA antibody titers were expressed as reciprocal sample dilutions giving absorbances of 3 times the background level. Opsonophagocytic activity of serum samples was assessed by measurement of in vitro killing, as reported elsewhere [17] .
RESULTS

Expression of GBS island 1 in
Lactococcus species. GBS pilus 1 is composed of 3 proteins containing LPXTG-like and pilin motifs (GBS80, GBS52, and GBS104), the first of which is essential for polymerization and constitutes the backbone of the pilus, whereas the other 2 are ancillary proteins [2] . The 3 proteins are encoded in genomic island 1 as a single transcriptional unit, together with 2 sortases catalyzing pilus assembly ( figure 1A) .
In an attempt to express GBS pilus 1 in L. lactis, the complete island 1 region, including the upstream putative promoter, was amplified from GBS COH1 and was inserted into the shuttle vector pAM401 [13] , generating the recombinant plasmid pAM-Is1. Two additional plasmid constructs, expressing each of the single LPXTG proteins, pAM-GBS80 and pAM-GBS104, were obtained in parallel.
After transformation of Lactococcus species with pAM-Is1, the expression of the 3 LPXTG proteins and their assembly into polymeric structures was tested by immunoblot analysis of total cell extracts by use of specific antisera (figure 1B). In addition to bands corresponding to the 3 monomeric proteins, a ladder of high-molecular-weight bands of similar pattern and slightly higher intensity than those observed in cell extracts of GBS COH1 was detected. In contrast, only a single band corresponding to the monomeric form of the protein was detected in bacteria expressing either GBS80 or GBS104 alone and, as expected, no bands were observed in lactococci carrying the empty vector pAM401 (L. lactis-pAM401).
To verify that GBS pilin components were exposed on the surface of Lactococcus, bacteria were subjected to fluorescenceactivated cell-sorting analysis using monoclonal antibodies against the protective antigens GBS80 and GBS104. As shown in figure 1C , both monoclonal antibodies specifically bound to recombinant bacteria expressing the whole pilin operon, and fluorescence shifts over the background were even higher than those observed for wild-type GBS COH1. L. lactis (pAM401), L. lactis (pAM-GBS80), and L. lactis (pAM-GBS104) all exhibited background levels of fluorescence.
The presence of GBS pili on the surface of Lactococcus was confirmed by transmission electron microscopy. Pilin-like structures extending beyond the cell wall could be observed in L. lactis (pAM-Is1) ( figure 1D and 1E ). GBS80 appeared to be more abundant than GBS104, confirming previous observations involving S. agalactiae, in which GBS80 constitutes the pilus backbone [2, 7] .
Overall, these data indicate that introduction of the entire pilin operon is sufficient to guide the efficient expression and assembly of GBS fimbriae in Lactococcus species, whereas, in the absence of the other components, the expression of single LPXTG proteins does not result in protein oligomerization and pilus formation.
Protection studies with lactococci expressing GBS pilus 1. It is well established that human antibodies against GBS antigens are transplacentally transferred to the fetus and protect newborns from GBS infection for the first 90 days after birth [18, 19] . Therefore, to test the potential of Lactococcus expressing GBS pili as a vaccine, we immunized female mice subcutaneously with live recombinant bacteria and analyzed the survival of their offspring after GBS lethal challenge. Parenteral immunization was chosen for the first attempt, given that commercial vaccines are mainly administered via this route. As shown in table 2, when mice received as little as 10 7 cfu of L. lactis (pAM-Is1), 170% of the pups survived the bacterial chal- lenge. This level of protection was comparable to that obtained by immunizing with recombinant GBS80 formulated with complete Freund adjuvant. The fact that the Lactococcus vaccine did not require adjuvant to be effective suggested that lactococcal cells acted as immunopotentiator. This was supported by the high protection levels obtained when mice were immunized with a mix of recombinant GBS80 and 10 7 cfu of recipient L. lactis (table 2) .
We subsequently investigated the capacity of L. lactis (pAMIs1) to confer protection by mucosal immunization. Statistically significant protection ( ) was obtained in the offspring P ! .0002 of mice immunized intranasally with 10 10 and 10 11 cfu of bacteria (table 2) .
Having demonstrated the prophylactic properties of piliated live lactococci, we investigated whether the observed protection correlated with maternal antibody titers in both subcutaneously and intranasally vaccinated mice. To this end, blood samples were collected from immunized mice 1 week before delivery and were analyzed by ELISA for specific responses against GBS80. All protective doses of L. lactis (pAM-Is1) elicited high titers of anti-GBS80-specific IgG ( figure 2A) .
In intranasally vaccinated mice, we also measured the levels of GBS80-specific IgA and IgG in nasal and vaginal lavages. As shown in figure 2B , specific secretory IgA appeared to be present not only in the nasal site of immunization but also on the vaginal mucosa of mice who received L. lactis (pAM-Is1). Although we did not investigate the functional properties of these antibodies, this observation might be significant, considering that, in humans, the genital tract is a primary site of GBS colonization.
Expression of hybrid pili and multistrain protection studies. Elsewhere, we have shown that immunization with mixtures of recombinant proteins from pilus 1 and pilus 2 conferred cross-protection against GBS strains carrying either of the 2 pilus types [8] . Similar results are expected in mice immunized with Lactococcus expressing either both types of pili or "hybrid" structures constituted by pilus 1 and pilus 2 components. We attempted this latter strategy by generating an island 1 derivative in which the gene coding for the ancillary protein GBS104 was removed from pAM-Is1 and replaced with the gene coding for its homolog GBS67 (43% identity between the 2 proteins), obtained from the genome of island 2-specific GBS 515 strain ( figure 3A) .
The newly generated plasmid pAM-Is1-2 was introduced into L. lactis MG1363, and recombinant bacteria were analyzed by Western blot. A ladder of high-molecular-weight bands, which reacted with serum samples specific for GBS80 and for GBS67, was observed (figure 3B), indicating that the hybrid island could guide the expression of the 2 proteins and their subsequent polymerization. The efficiency of polymerization of GBS80 was comparable to that obtained for pAM-Is1, whereas, based on image analysis, the estimated amount of GBS67 in the polymers was approximately one-third of that observed with GBS104.
The 2 polymerized proteins were found to be surface associated, as judged by fluorescence-activated cell sorting analysis (data not shown). In contrast, and similar to what was observed for pAM-GBS80 and pAM-GBS104, polymerization did not occur in Lactococcus expressing exclusively GBS67 (L. lactis [pAM-GBS67]), for which background levels of fluorescence were detected.
Electron microscopy images of L. lactis (pAM-Is1-2) confirmed the colocalization of the 2 proteins in a single pilus structure. Cells were incubated both with rabbit antibodies against GBS80 and with mouse antibodies specific for GBS67 and subsequently were exposed to 5 nm of anti-rabbit and 10 nm of anti-mouse gold-labeled secondary antibodies. As shown in figure 3C , GBS80 represented the major pilus component, whereas GBS67 was much less abundant, as observed for GBS104 in L. lactis (pAM-Is1) ( figure 1D) .
We subsequently investigated whether immunization with lactococci harboring hybrid pili conferred cross-protection against GBS strains expressing either of the 2 pilus types. Female mice were immunized subcutaneously with 10 10 cfu of L. lactis (pAMIs1-2) or with L. lactis (pAM-Is1), and pups were challenged either with COH1 GBS strain, expressing pilus 1 but not pilus 2, or with 515 strain, which carries only pilus 2. As shown in table 3, the offspring of mice that received either L. lactis (pAMIs1) or L. lactis (pAM-Is1-2) were protected against lethal chal- lenge with COH1. Protection against pilus 2-specific strain 515 was instead achieved exclusively on immunization with bacteria carrying hybrid pili. As expected, adjuvanted purified GBS80 and GBS67 proteins protected against COH1 and 515, respectively. We further tested the protective activity of bacteria expressing the GBS67 protein alone (L. lactis [pAM-GBS67]) against 515. In spite of the high level of protein expression (figure 3B), protection values were lower than the ones measured with lactococci expressing hybrid pili, suggesting a better antigen presentation to the host immune system when the protein is exposed to the bacterial surface as part of a pilus polymer.
The mechanism by which anti-GBS maternal antibodies confer protection involves complement-mediated phagocytosis of opsonized bacteria and their subsequent killing [18, 20] . Consistent with protection data, serum samples from mice immunized with L. lactis (pAM-Is1-2) promoted killing of both GBS COH1 (pilus 1) and 515 (pilus 2) by human leukocytes (figure 4). In contrast, serum samples from mice immunized with L. lactis (pAM-Is1) mediated the phagocytosis of GBS COH1 but not of 515. In the latter case, the observed marginal growth inhibition could be due to the capacity of antibodies against GBS104 of pilus 1 to cross-react with the partially homologous GBS67.
DISCUSSION
Recent investigations [2, 9, 10] have indicated that the major pathogenic streptococci express surface-associated, long, piluslike structures protruding out of the thick protective capsules surrounding the bacterial cell. These structures, formed by proteins with adhesive functions, are likely to be implicated in host colonization and virulence. From genome analysis, it appears that streptococcal loci involved in pilus formation have typical features of pathogenicity islands. For instance, they differ in GC content from the rest of the genome, they are usually flanked by insertion elements, and they contain known virulence factors [21] .
In the present study, we show, for the first time, that an entire pilin island can be transferred from GBS to a nonpathogenic species and that recombinant bacteria acquire the capacity to produce pilus-like structures on their surface. This result strongly supports the notion that streptococcal pili are encoded in pathogenicity islands that can be mobilized horizontally among different strains and species. This provides an evolutionary explanation for the presence of pili in all pathogenic streptococci and for their overall similar genetic organization.
DNA sequencing analysis revealed that the variability of pilus components within strains of the same species is comparable to the variability observed among pili from different species. For instance, GBS104 from GBS pilus 1 displays 43% homology both to GBS67 of GBS pilus 2 and to RrgA pilus component of S. pneumoniae. The second important observation emerging from our study is that, by combining genes from different islands, hybrid structures containing elements from different pilus types can properly assemble. This suggests reshuffling between recipient and horizontally acquired pilus islands as a means to generate pilus variability, which in turn may help streptococcal pathogens to gain new ecological niches.
Probably the most relevant result of our work is the demonstration that nonpathogenic bacteria expressing properly assembled pilus-like structures from GBS are effective live vaccines against neonatal GBS infections, as demonstrated using a mouse model of maternal immunization. Protection is mediated by the elicitation of functional antibodies and is achieved when bacteria are delivered either systemically or mucosally.
GBS is a widespread microorganism that colonizes 15%-35% of healthy women [22] , but it can also cause overwhelming neonatal infections as a result of direct transmission of the bacteria from colonized pregnant women to their babies. It has been clearly demonstrated that the risk of neonatal infection is inversely proportional to the maternal amount of specific antibodies to the capsular polysaccharide, which are transferred from the mothers to the babies through the placenta [18, 19] . Vaccines based on protein-conjugated capsular polysaccharides from different serotypes have been tested in clinical trials with promising results [23] However, because of the high variability of the capsular polysaccharide (9 serotypes have been described, in addition to an emerging number of nontypeable isolates), glycoconjugate vaccines not only require complex formulations but also hardly confer full protection.
On the basis of the protective activity of GBS pili protein components and the data presented here, one can envisage broad-coverage live vaccines developed by expressing simultaneously in a nonpathogen elements from different GBS pilus types. For example, we show that the genetic manipulation of GBS islands 1 and 2 can guide the expression of hybrid pili containing components of the 2 different pilus types in Lactococcus and that recombinant bacteria can confer multistrain protection.
Food-grade bacteria have received growing attention as delivery systems for the production of safe and low-cost vaccines, and several heterologous proteins have been expressed in the "generally recognized as safe" L. lactis species for this purpose [24, 25] . Few examples of live vaccine compositions inducing specific immune responses and protection in animal models have been reported [26] [27] [28] . No toxic activity associated with the bacterial host was observed in those studies. This is consistent with our data showing that neither mucosal nor systemic administration of 10 10 or 10 11 cfu of Lactococcus species resulted in any observable adverse effect in immunized mice.
As mentioned above, GBS colonizes the anogenital mucosa of healthy women, and the bacterial load at mucosal level correlates with the risk of intrapartum transmission and infection [29] . Vaccines inducing not only protective antibodies that can be transplacentally transferred to the fetus but also mucosal antibodies preventing colonization of the mothers are expected to further contribute to neonate protection. Although we have not investigated the functional activity of the mucosally secreted antibodies, our results, indicating that intranasal delivery of lactococci expressing GBS pili elicits specific secretory IgA both at nasal and vaginal sites and that immunized mice protect their neonates, suggest that the use of live recombinant L. lactis as mucosal vaccines deserves further investigation.
Streptococcal pilus components display homology with known adhesins mediating bacterial attachment and colonization of epithelial mucosae and eventually host infection. In the case of GAS pili, the capacity of 1 of the pilus components to bind human type 1 collagen has been clearly demonstrated [30] . It is thus conceivable that pilus-like structures contribute to the virulence of major streptococcal pathogens. Although immunization of mice with nonpathogenic bacteria expressing streptococcal pili did not result in any observable effects on the animals' health, further studies are underway to address the contribution of streptococcal fimbriae to virulence.
This study paves the way for the development of simple formulations of multivalent live vaccines in which pilin elements from different streptococcal species are combined in a single recombinant clone, providing broad intra-and interspecies protection against streptococcal infections. This is particularly relevant in view of the urgent need for efficacious preventive measures in developing countries, where endemic streptococcal infections are responsible for high morbidity and a large number of fatalities.
